PROVENCHER, DIANE

 Rozenholc A, Samouëlian V, Warkus T, Gauthier P, Provencher D, Sauthier P, Gauthier F, Cormier, B. Green vs Blue: Randomised Controlled Trail of lndocyanine Green vs Methylene Blue for Sentine! Lymph Node

Procedure in Endometrial Cancer. Gynecologic Oncology, Volume 153, Issue 3, June 2019, Pages 500-504

 Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Provencher D, et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun. 2019 Jun 11;10(1):2556

 Zaoui K, Boudhraa Z, Khalifé P, Carmona E, Provencher D, Mes-Masson AM. Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nat Commun. 2019 Jun 17;10(1):2666

 De Boer SM, Powell ME, Mileshkin L, Katsaros D, Paul Bessette, Christine Haie-Meder, Provencher D, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019 Sep;20(9):1273-1285

 Asare-Werehene M, Communal L, Carmona E, Le T, Provencher D, Mes-Masson AM, Tsang B. Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. Sei Rep 2019 Sep 26;9(1):13924

 Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Arharasinghe KC, Ananda S, Provencher D, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019 Sep 2;10(1):3935

 Tinker AV, Hirte HW, Provencher D, Butler MO, Ritter H, Tu D, Azim HA, Paralejas P, et al. Dose-ranging and cohort-expansion study of monalizumab(JPH2201) in advanced gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG):IND221. Clinical Cancer Research:25(20):6052 -6060,2019

 Le Page C, Chung J, Rahimi K, Kobel M, Provencher D, Mes-Masson AM.

Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. Curr Drug Targets 2019 Oct 16

 Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P et al. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol 2019 Nov 10;37(32):2968-2973

 Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Provencher D, et al. Clinicopathological Features of Women With

101 Epithelial Ovarian Cancer and Double Heterozygosity for BRCA1 and BRCA2: A Systematic Review and Case Report Analysis. Gynecol Oncol 2020 Feb;156(2):377-386

 Arend RC, Davis AM, Chimiczewski P, O'Malley D, Provencher D, Vergote I, Ghamande S, et al. EMR 20006--012: A Phase Il Randomized Double-Blind Placebo Controlled Trial Comparing the Combination of Pimasertib (MEK inhibitor) with SAR245409 (Pl3K inhibitor) to Pimasertib Alone in Patients with Previously Treated Unresectable Borderline or Low Grade Ovarian Cancer. Gynecol Oncol 2020 Feb;156(2):301-307

 Oza A, Matulonis U, Secord AA, Nemunaitis J, Roman L, Blagden S, Banerjee S, Provencher D, et al. A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. Clin Cancer Res 2020 Mar 1;26(5):1009-1016

 Trinh VQ, Pelletier MP, Echelard P, Warkus T, Sauthier P, Gougeon F, Mès-Masson AM, Provencher D, Rahimi K. Distinct histologie, immunohistochemical and clinical features associated with serous endometrial intraepithelial carcinoma developed in polyps. lnt J Gynecol Pathol 2020 Mar;39(2):128- 135

 Fernandez ML, Dawson A, Kim H, Lam N, Russell H, Bruce M, Hoenisch J, Provencher D, et al. Hormone Receptor Expression and Outcomes in Law-Grade Serous Ovarian Cancer. Running Title: Hormone Receptors in LGSC.

Gynecol Oncol. 2020 Apr;157(1):12-20

 Boudhraa Z, Carmoria E, Provencher D, Mes-Masson AM. Ran GTPase: A key player in tumor progression and metastasis. Front. Cell Dev. Biol., 26 May 2020

 Grundy A, Ho V, Abrahamowicz M, Parent MÉ, Siemiatycki J, Arseneau J, Gilbert L, Gotlieb WH, Provencher D, Koushik A. Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-contrai study. lnt J Cancer. 2020 Apr 1;146(7):1800-1809

 Communal L, Medrano M, Sircoulomb F, Paterson J, Hoskins P, Provencher D, et al. Low Junctional Adhesion Molecule A Expression is Associated with an Epithelial to Mesenchymal Transition and Poorer Outcomes in Tubo-Ovarian High-Grade Serous Carcinoma. Accepté par Modem Pathology. Mai 2020

 Kang EY, Cheasley D, Le Page C, Wakefield M, da Cunha Torres M, Rowley S, Provencher D, et al. Refined eut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors:

implications for outcome analyses. Accepté pour publication par Modem Pathology, juin 2020

 Oza AM, Estevez-Diz M, Grischke AM, Hall M, Marmé F, Provencher D, et al. A biomarker-enriched, randomized, Phase Il trial of adavosertib (AZD1775) plus paclitaxel and carboplatin forwomen with platinum-sensitive TP53-mutant ovarian cancer. Matériel supplémentaire: An international, biomarker-enriched, randomised, Phase Il trial of AZD1775 plus paclitaxel and carboplatin for the treatment of women with platinum-sensitive TP53-mutant ovarian cancer. Accepté par le journal Clinical cancer Research, 1er juillet 2020

 Sauriol A, Simeone K, Portelance L, Meunier L, Leclerc-Desaulniers K, Provencher D, et al. Modeling the diversity of epithelial ovarian cancer through ten navel well characterized cell lines covering multiple subtypes of the disease. Acepté pour publication par le journal Cancer. Août 2020

 Provencher D, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Soumis au Journal of Pathology. Août 2020

 Boudhraa Z, Zaoui K, Gilbert S, Fleury H, Cahuzac M, Provencher D, et al.

NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer. Soumis à Nature Cancer. Août 2020

 Bareche Y, Pommey S, Carneiro M, Cousineau I, Chrobak P, Allard D, Provencher D, et al. High-climensional analysis of the adenosine pathway in high grade serous ovarian cancer. Soumis au journal Annals of Oncology. Juillet 2020

 Patra B, Lateef MA, Nourmoussavi Brodeur M, Fleury H, Carmona E, Provencher D, et al. Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. (En prépartion, Mai 2020)

 Le Page C, Provencher D, et al. SATB2 expression in endometrial stromal sarcoma: A multicenter retrospective study. EXPRESSION IN ENDOMETRIAL STROMAL SARCOMA: A MULTICENTER RETROSPECTIVE STUDY" (the "Work"), by Dr Cecile Le Page, to International Journal of Gynecological Pathology

 Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Bedard K, Provencher D, et al. The genetic analysis of a founder Northem American population of European descent identifies FANCI as a candidate familial

102 ovarian cancer risk gene. Soumis à Nature Genetics, semaine du 25 mai 2020

 Provencher D. LIGHT: NCT02983799; a non-randomised, open- label Il stydy to assess olaparib tablets as a treatment forsubjects with different HRD tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer that have received at least 1 prior line of chemotherapy). En redaction. Mai 2020

 Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Provencher D, et al. Molecular and clinical determinants of response and resistance to the PARP inhibitor rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Soumis à Nature Medicine, Avril 2020

 Tinker AV, Hirte HW, Provencher D, Butler M, Ritter H, Tu D, Azim Jr HA, et al. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. Clin Cancer Res 2019;25:6052-60

 Scott SA, Uaurado M, Elit L, Nourmoussavi M, Glaze S, Roberts L, Offman SL, Provencher D, et al. Low Grade Serous Carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecol Oncol 2020 Apr;157(1):36-45

 Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lime P, Castro C, Provencher D, et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (AOC), in combination with bevacizumab (BEV) in patients (pts) with platinum-agnostic ovarian cancer. ASCO 2020

 Hardy-Bessard AC, Moore KN, Mirza MR, Asselain B, Redondo A, Pfisterer J, Provencher D, et al. ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy ± Dostarlimab Followed by Niraparib ± Dostarlimab Maintenance as First-Line Treatment of Stage Ill or Stage IV Ovarian Cancer. Soumis à ASCO 2020

 Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Provencher D, et al. Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC). ASCO 2020

 Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Provencher D, et al. Population safety and exposure--efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2. Présenté à SGO 2020

 Castonguay V, Provencher D. DPX-Survivac and pembrolizumab with or without intermittent low dose cyclophosphamide (CPA) for the treatment of advanced and metastatic ovarian cancer: Efficacy and safety results from Phase 2 study. Présenté à ASCO 2020

 Hardy-Bessard AC, Provencher D. ENGOT-OV44/FIRST study: a randomized, double- blind, adaptive, phase 3 study of standard of care (SOC) platinum-based therapy dostarlimab followed by niraparib dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). Présenté à ASCO 2020

 Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Provencher D, et al. Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC). Présenté à ASCO 2020

 Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim P, Castro C, Provencher D, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (AOC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

Présenté à ASCO 2020

 Scott SA, Llaurado Femandez M, Kim H, Elit L, Nourrnoussavi M, Glaze S, Provencher D, et al. Assessing variation in practice and outcomes in low grade serous carcinoma (LGSC): Importance of systematic data collection in rare gynecologic cancers. Soumis à GOC/CCOCR

 Provencher D, Le cancer de l'ovaire pendant la pandémie de la COVID-19.

Politique de santé. Présentation par webinar d'une durée de 1 heure aux patientes en gynécologie oncologique. Montréal, Québec. 9 juin 2020

 Provencher D. Comité consultatif régional d'AstraZeneca et Merck sur le cancer de l'ovaire. La génétique présentée avec Dr Stéphanie L'Heureux.

Hôtel Nelligan. Montréal, Québec. 20 juin 2019

 Provencher D. Cours aux résidents en hémato-onco: Onco-génétique 2019. CHUM, 15h à 17h. Montréal, Québec. 7 août 2019

 Provencher D, Mes-Masson AM. 10^e Journée scientifique du CRCHUM.

Vision, Team and Respect: Essential Building Blocks for Success. CRCHUM.

Montréal, Québec. 17 octobre 2019

103

 Provencher D. Mise à jour sur la prise en charge du cancer de l'ovaire et l'utilisation des inhibiteurs de PARP (PARPi). Hôpital Sacré-Cœur.

Montréal, Québec. 25 octobre 2019

 Provencher D. SEMO-Retour sur ESMO 2019. CHUM. Montréal, Québec.

18 novembre 2019

 Provencher D. Évolution du leadership médical. Présentation: Projet sur le cœur et... CHUM. Montréal, Québec. 20 novembre 2019

 Provencher D. Mise à jour sur la prise en charge du cancer de l'ovaire et l'utilisation des inhibiteurs de PARP (PARPi). Hôpital de Saint-Jérôme.

Saint-Jérôme, Québec. 6 février AM 2020

 Provencher D. SEMO - PARPi le choix du chef! Retour sur NRG. CHUM, 10 février 2020

 Provencher D. Mise à jour sur la prise en charge du cancer de l'ovaire et l'utilisation des inhibiteurs de PARP (PARPi). Hôpital Pierre-LeGardeur.

Terrebonne, Québec. 20 février AM 2020

 Provencher D. Le dépistage du cancer de l'ovaire, où sommes-nous rendus? CMQ. Montréal, Québec. 12 mars 2020